Selective A2A, but not A1 adenosine antagonists enhance the anticataleptic action of trihexyphenidyl in rats

Neuroscience Letters

Volumn 346, Issue 1-2, 2003, Pages 1-4

  Villanueva Toledo, Jairo ^a   Moo Puc, Rosa E ^a   Góngora Alfaro, José L ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

^b NONE   (Mexico)

Author keywords

4 (2 7 Amino 2 (2 furyl)1,2,4 triazolo 2,3 a 1,3,5 triazin 5 ylamino ethyl)phenol; 8 Cyclopentyl 1,3 dipropyl xanthine; Anticholinergic; Catalepsy; Parkinson; Synergism

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; HALOPERIDOL; MUSCARINIC RECEPTOR BLOCKING AGENT; TRIHEXYPHENIDYL; ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG SELECTIVITY; LATENT PERIOD; MALE; MEDICAL ASSESSMENT; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; TASK PERFORMANCE; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; PHYSIOLOGY; WISTAR RAT;

ANIMALS; CATALEPSY; DRUG SYNERGISM; MALE; MUSCARINIC ANTAGONISTS; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; TRIHEXYPHENIDYL;

EID: 0037707692     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00337-9     Document Type: Article

References (20)

1. De Boer P., Abercrombie E.D. Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes. J. Pharmacol. Exp. Ther. 277:1996;775-783.
2. De Boer P., Abercrombie E.D., Heeringa M., Westerink B.H.C. Differential effect of systemic administration of bromocriptine and L-DOPA on the release of acetylcholine from striatum of intact and 6-HODA-treated rats. Brain Res. 608:1993;198-203.
3. 2A receptor knockout mice are partially protected against drug-induced catalepsy. NeuroReport. 12:2001;983-986.
4. Ezrin-Waters C., Muller P., Seeman P. Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs. Can. J. Physiol. Pharmacol. 54:1976;516-519.
5. Fahn S., Burke R., Stern Y. Antimuscarinic drugs in the treatment of movement disorders. Prog. Brain Res. 84:1990;389-397.
6. Ferré S., Popoli B., Giménez-Llort L., Rimondini R., Müller C.E., Strömberg I., Ögren S.O., Fuxe K. Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease, Parkinsonism Relat. Disord. 7:2001;235-241.
7. 2A receptor antagonist in MPTP-treated monkeys. Neurology. 52:1999;1673-1677.
8. 3H]acetylcholine release. J. Neurochem. 62:1994;960-966.
9. Kirkpatrick K.A., Richardson P.J. Adenosine receptor-mediated modulation of acetylcholine release from rat striatal synaptosomes. Br. J. Pharmacol. 110:1993;949-954.
10. 2a receptor-mediated modulation of striatal acetylcholine release in vivo. J. Neurochem. 66:1996;1882-1888.
11. 2 receptors modulate haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 328:1997;135-141.
12. R.E. Moo-Puc, J.L. Góngora-Alfaro, F.J. Alvarez-Cervera, J.C. Pineda, G. Arankowsky-Sandoval, F. Heredia-López, Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy, Neuropharmacol (2003) in press.
13. Nehlig A., Boyet S. Dose-response study of caffeine effects on cerebral functional activity with a specific focus on dependence. Brain Res. 858:2000;71-77.
14. 2A antagonists. Il Farmaco. 56:2001;87-90.
15. Richardson P.J., Dixon A.K., Lee K., Bell M.I., Cox P.J., Williams R., Pinnock R.D., Freeman T.C. Correlating physiology with gene expression in striatal cholinergic neurones. J. Neurochem. 74:2000;839-846.
16. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol. Sci. 18:1997;338-344.
17. Sanberg P.R., Martinez R., Shytle R.D., Cahill D.W. The catalepsy test: is a standardized method possible? Sanberg P.R., Ossenkoop K.-P., Kavaliers M. Motor Activity and Movement Disorders. 1996;197-211 Humana Press, Totowa, NJ.
18. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology. 147:1999;90-95.
19. Stoof J.C., Drukarch B., De Boer P., Westerink B.H.C., Groenewegen H.J. Regulation of the activity of striatal cholinergic neurons by dopamine. Neuroscience. 47:1992;755-770.
20. 2 receptor regulation of apomorphine-induced turning in rats with unilateral striatal dopamine denervation. Psychopharmacology. 111:1993;383-388.